MedTrace Logo

Liver Transplantation and Uveal Malignant Melanoma

NCT01311466 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-10-23

No results posted yet for this study

Summary

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Conditions

  • Uveal Malignant Melanoma

Interventions

PROCEDURE

Liver transplantation

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Svein Dueland, MD, PhD · Oslo University Hospital, Radium hospitalet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311466 on ClinicalTrials.gov